Eccrine Squamous Syringometaplasia Associated with Pelubiprofen Therapy

Abstract

Eccrine squamous syringometaplasia (ESS) is a histologically distinctive skin eruption occurring predominantly in acral or intertriginous areas presenting as erythematous macules, papules or patches. The etiology of ESS remains unclear, but it is usually reported in patients receiving chemotherapy for various malignant neoplasms. To date, only two cases of ESS associated with non-steroidal anti-inflammatory drugs (NSAIDs), which has distinctive clinical features and pathogenesis, have been reported in the literature. Herein, we report a rare and interesting case of ESS associated with pelubiprofen, a recently developed NSAID, which appeared after pelubiprofen therapy and resolved spontaneously after discontinuing the medication.

Eccrine squamous syringometaplasia associated with Natalizumab

“…To our knowledge, only four cases of ESS in association with nonchemotherapeutic agents have been reported (Table S1). ESS has been reported in association with antipsychotic drugs (olanzapine), 9 nonsteroidal anti-inflammatory medications (NSAIDs) such as Benoxaprofen 10 and Pelubiprofen, 11 as well as Amineptine, a synthetic tricyclic antidepressant. 12 The clinical and histological differences represent a clinical diagnostic challenge as the clinical presentation of ESS is nonspecific.…”